Latest Zyprexa Stories

INDIANAPOLIS, April 24, 2013 /PRNewswire/ -- Worldwide revenue was flat as growth in key products offset lower Zyprexa revenue following patent expirations. Cymbalta revenue increased 19 percent while Cialis increased 11 percent. Expense controls resulted in lower SG&A, offsetting growth in R&D expense. First quarter 2013 results include income of $495 million related to the transfer to Amylin of exenatide commercial rights outside of the U.S. Tax rate comparisons...

INDIANAPOLIS, Oct. 24, 2012 /PRNewswire/ -- Worldwide revenue declined 11 percent to $5.443 billion, driven by Zyprexa patent expirations. Cymbalta revenue increased 16 percent due to continued growth in both the U.S. and international markets. Third-quarter earnings per share were $1.18 (reported), or $0.79 (non-GAAP, when excluding income from Amylin payment and asset impairment and restructuring charge). Data read-outs provided a better understanding of several potential...

INDIANAPOLIS, July 25, 2012 /PRNewswire/ -- Worldwide revenue declined 10 percent to $5.6 billion, driven by Zyprexa patent expirations, partially offset by significant growth in other products. Cymbalta revenue increased 22 percent due to continued strong growth in both the U.S. and international markets. China and Japan delivered pharma revenue growth of 28 percent and 15 percent, respectively, providing counter-cyclical growth. Elanco Animal Health continued its strong...

INDIANAPOLIS, April 25, 2012 /PRNewswire/ -- Worldwide revenue declined 4 percent in the first quarter of 2012, driven by Zyprexa patent expirations, partially offset by significant growth in other products and key regions. Cymbalta revenue increased 23 percent due to strong growth in both the U.S. and international markets, while Effient revenue more than doubled. Elanco Animal Health revenue grew 33 percent, driven by gains in both the food animal and companion animal...

INDIANAPOLIS, Jan. 31, 2012 /PRNewswire/ -- Fourth quarter revenue declined two percent driven by Zyprexa and Gemzar patent expirations, partially offset by growth in other products.Fourth quarter earnings per share were $.77 (reported), or $.87 (non-GAAP).Full-year 2011 revenue grew five percent, topping $24 billion, as seven pharmaceutical products and the company's animal health business all exceeded $1 billion in annual sales.Full-year 2011 earnings per share totaled $3.90 (reported),...

In the news release, Lilly Comments on 2011 Financial Guidance and Announces 2012 Financial Guidance, issued Jan. 5, 2012 by Eli Lilly and Company over PR Newswire, we are advised by the company that the second paragraph, second sentence, should read "and $.18 of asset impairment " rather than "and $.13 of asset impairment" as originally issued inadvertently. The complete, corrected release follows: Lilly Comments on 2011 Financial Guidance and Announces 2012 Financial Guidance...

INDIANAPOLIS, Jan. 5, 2012 /PRNewswire/ -- Company expects to meet or exceed 2011 EPS guidance. 2012 financial guidance reflects revenue and earnings declines due to Zyprexa patent expiration. 2012 revenue anticipated to be between $21.8 billion and $22.8 billion. Company expects to keep 2012 operating expenses essentially flat versus 2011. 2012 earnings per share forecasted to be in the range of $3.10 - $3.20. R&D pipeline includes 12 molecules in Phase III development at...

INDIANAPOLIS, Oct. 20, 2011 /PRNewswire/ -- Third-quarter 2011 revenue grew 9 percent to $6.148 billion due to increased demand for several key brands and favorable exchange rates.Revenue for Cymbalta, Humalog, Forteo, Strattera, Cialis and Alimta all grew in double-digits, with strong growth also seen in animal health, Japan and China.Q3 operating expense growth was driven primarily by marketing efforts to support new launches, investments in research and development, and exchange...

INDIANAPOLIS, July 22 /PRNewswire-FirstCall/ -- Nine percent revenue growth driven by higher volume continues strong trend for the year.21 percent of Q2 revenue invested in R&D to advance pipeline of nearly 70 potential new medicines in clinical development.Ongoing cost-containment efforts support double-digit growth in operating income.Q2 earnings per share grow to $1.22 (reported), or $1.24 (non-GAAP).2010 earnings per share guidance range raised to $4.44 to $4.59 (reported), or...

WALTHAM, Mass., April 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed psychiatrists say that the decrease in severity of manic symptoms is the attribute that most influences their prescribing decisions in bipolar mania. Clinical data and the opinions of interviewed thought leaders indicate that Eli Lilly's Zyprexa (olanzapine) has advantages in this attribute over...